Related Experiment Video
Updated: Mar 9, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR
Megumi Funakoshi-Tago1, Takuro Moriwaki1, Fumihito Ueda1
1Department of Hygienic Chemistry, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
Abstract:
The JAK2 V617F mutant-mediated aberrant signaling pathway is a hallmark of myeloproliferative neoplasms (MPNs). Although cytokine-inducible Src homology 2 protein (CIS) and suppressors of cytokine signaling (SOCS) are negative regulators of the JAK-STAT pathway, the functional role of CIS/SOCS family members in the JAK2 V617F mutant-induced oncogenic signaling pathway has not yet been elucidated. In this study, we found that the expression of CIS and SOCS1 was induced through the activation of signal transducer and activator of transcription 5 (STAT5) in not only the cells stimulated with Epo or IL-3 but also the cells transformed by the JAK2 V617F mutant. Cell proliferation and tumor formation in nude mice induced by the JAK2 V617F mutant were significantly enhanced when the expression of CIS was silenced using an RNA interference technique, whereas the knockdown of SOCS1 had no effect. The enforced expression of CIS caused apoptotic cell death in the transformed by JAK2 V617F mutant and drastically inhibited the JAK2 V617F mutant-induced tumor formation. CIS interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 and ERK. Whereas the activation of STAT5 and ERK in the transformed cells by JAK2 V617F mutant was increased by the knockdown of CIS, the enforced expression of CIS reduced the activation of these molecules. Furthermore, these anti-tumor effects of CIS required the function of SH2 domain and its tyrosine phosphorylation at Y253. We herein elucidated the mechanism by which CIS functions as a novel type of tumor suppressor in JAK2 V617F mutant-induced tumorigenesis.
Insights
Cytokine-inducible Src homology 2 protein (CIS) acts as a tumor suppressor in myeloproliferative neoplasms (MPNs) by inhibiting JAK2 V617F signaling. Its enforced expression reduces tumor formation and induces apoptosis, highlighting its therapeutic potential.
Area of Science:
- Molecular Biology
- Oncology
- Signal Transduction
Background:
- Myeloproliferative neoplasms (MPNs) are characterized by aberrant JAK2 V617F signaling.
- Negative regulators of the JAK-STAT pathway, such as CIS and SOCS, are implicated in MPNs, but their specific roles are unclear.
Purpose of the Study:
- To elucidate the functional role of CIS and SOCS family members in JAK2 V617F mutant-induced oncogenic signaling.
- To investigate the mechanism by which CIS suppresses tumor formation in MPNs.
Main Methods:
- RNA interference (RNAi) to silence CIS and SOCS1 expression.
- Enforced expression of CIS in JAK2 V617F mutant-transformed cells.
- Analysis of STAT5 and ERK activation.
- Assessment of tumor formation in nude mice.
- Investigation of CIS interaction with phosphorylated EpoR and its SH2 domain function.
Main Results:
- CIS expression is induced by STAT5 activation in JAK2 V617F mutant cells.
- Silencing CIS enhanced cell proliferation and tumor formation; silencing SOCS1 had no effect.
- Enforced CIS expression inhibited tumor formation and induced apoptosis.
- CIS interacts with phosphorylated EpoR, inhibiting STAT5 and ERK activation.
- CIS's anti-tumor effects depend on its SH2 domain and tyrosine phosphorylation at Y253.
Conclusions:
- CIS functions as a novel tumor suppressor in JAK2 V617F mutant-induced tumorigenesis.
- CIS inhibits oncogenic signaling by interacting with phosphorylated EpoR, thereby suppressing STAT5 and ERK activation.
- Targeting CIS may offer a therapeutic strategy for MPNs.
Related Concept Videos
The JAK-STAT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

